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Abstract 
Photoacoustic imaging (PAI) is an emerging tool that bridges the traditional depth 
limits of ballistic optical imaging and the resolution limits of diffuse optical imaging. 
Using the acoustic waves generated in response to the absorption of pulsed laser 
light, it provides non-invasive images of absorbed optical energy density at depths of 
several centimeters with a resolution of ~100 µm. This versatile and scalable imaging 
modality has now shown potential for molecular imaging, which enables visualization 
of biological processes non-invasively using systemically introduced contrast agents. 
Understanding the relative merits of the vast range of contrast agents reported, from 
small molecule dyes, through gold and carbon nanostructures, to liposome 
encapsulations, represents a significant challenge. Here, we critically review the 
physical, chemical and biochemical characteristics of the existing photoacoustic 
contrast agents, highlighting key applications and also the present challenges for 
molecular PAI. 
  
1. Introduction to molecular Photoacoustic Imaging (PAI) 
 
Molecular imaging aims to visualize and quantify biological processes at the 
molecular and cellular level in a non-invasive manner, providing an opportunity to 
detect, stage, predict and monitor the development of disease. As early as the 17th 
century, Anton van Leeuwenhoek and Robert Hooke used light to visualize cells. For 
medical imaging, however, light suffers from significant scattering in biological tissue, 
which requires a trade off between depth of penetration and spatial resolution. 
Microscopy and other techniques that utilize unscattered photons can provide high 
resolution imaging (~1 µm) but only up to a depth of  ~1 mm in most biological 
tissues; diffuse optical techniques such as fluorescence and near infrared optical 
tomography that exploit multiply scattered photons can provide penetration depths of 
several cm provided spatial resolution is sacrificed (>1 mm).1  
Photoacoustic imaging (PAI) is an emerging method that combines the high 
contrast of optical imaging with the high spatial resolution of ultrasound.2–4 Tissue 
heating due to the absorption of short laser pulses by endogenous chromophores or 
exogenous molecular imaging contrast agents produces broadband acoustic waves 
at MHz frequencies. These photoacoustic waves can be detected by ultrasound 
transducers at the tissue surface and reconstructed to form an image of the 
absorbed optical energy distribution. A brief explanation of the image formation 
process and required conditions for the image to represent absorbed optical energy 
can be found in Supplementary Note 1. Since sound waves are less scattered in 
tissue than photons, PAI can push the traditional limitations of optical imaging. For 
example, when operating in the ‘near-infrared (NIR) window’ (620 – 950 nm), 
tomographic PAI can reach a penetration depth of several cm with a resolution of the 
order of a few 100 µm, scaling to < 100 µm resolution for shallower (<1 cm) 
penetration depths.2 
Chromophores (light absorbing molecules) intrinsic to living systems such as 
hemoglobin5–7 and melanin8,9, provide structural and functional information in PAI.  
Building on this intrinsic contrast with advances in exogenous contrast agents, PAI is 
currently one of the fastest-growing molecular imaging techniques. Given that 
molecular PAI is relatively affordable and portable, it has been rapidly incorporated 
for preclinical imaging in vivo in small animals for a range of disease indications. In 
this realm, the prevailing application by far is in cancer research, where PAI has 
been explored for: primary tumor detection and molecular characterization10,11; 
therapeutic monitoring6; as well as for the identification and assessment of metastatic 
lymph nodes12.  
This review highlights the latest advances in exogenous contrast agents for 
molecular PAI. After a basic introduction to the considerations needed for in vivo 
molecular PAI, including discussion of the background endogenous PA contrast, we 
detail the physical, chemical and biochemical characteristics of available contrast 
agents. Given the widespread use in cancer research to date, we draw on this 
research field for key examples of molecular PAI throughout the article. An overview 
of the strengths and weaknesses of each approach is provided in the outlook, to help 
guide new investigators in the field towards an appropriate contrast agent for their 
application.  
  
 
2. Sources of endogenous contrast in PAI 
 
While the focus of this review is exogenous contrast agents, it is important to 
appreciate the capabilities of, and challenges presented by, background endogenous 
PA signals when performing molecular PAI.  
 
2.1. Intrinsic chromophores 
 
Endogenous PAI provides structural and functional information through light 
absorption by hemoglobin, lipids, water and melanin (Fig. 1a). Hemoglobin, a protein 
composed of four heme-containing polypeptides residing in red blood cells, delivers 
oxygen throughout the body. The heme group is an iron-containing aromatic 
porphyrin ring system that is strongly absorbing and experiences structural and 
electronic modifications upon oxygen binding (Fig. 1b). The resulting change in the 
absorption spectrum (Fig. 1a) offers the prospect of measuring total hemoglobin 
concentration (Hbtotal) and oxygen saturation (sO2), important for non-invasive 
visualization of tumor angiogenesis (Fig. 1c).5,6 PAI can also map lipid distribution in 
vivo13 based on the absorption peaks at 930 and 1210 nm (second overtone of 
abundant C-H bonds), while water can be identified based on the absorption peak at 
975 nm.14 Melanin is a ubiquitous natural pigment in skin, hair and eyes, with intense 
optical absorption; while strong skin pigmentation may present a limitation as it 
reduces the amount of light penetrating deep into tissue, it does enable sensitive 
characterization of primary melanoma15,9 and metastatic melanoma cells16. 
Nonetheless, these chromophores: probe only a limited range of biological 
processes; do not provide access to molecular information; and give a significant 
level of background absorption that must be accounted for when performing 
molecular imaging with exogenous contrast agents. 
 
2.2. Genetically encoded chromophores 
 
Most cells in the body are invisible to PAI in the NIR window. Reporter gene 
imaging enables visualization of the location and level of gene expression, promoter 
activity and protein-protein interaction in cells in vivo with PAI.17 Under the control of 
the promoter of the gene of interest, a reporter gene expresses proteins that either 
provide PA contrast directly or create a product that yields PA contrast (Fig. 2a). 
Reporter genes are suitable for applications where the cell or biological process of 
interest does not provide inherent PA contrast but use of a contrast agent is 
undesirable, for example, in longitudinal studies of tumor development. 
An example of a reporter gene system in which the expressed protein directly 
provides contrast is the genetically encoded green fluorescent protein (GFP) family 
of proteins.18 The GFP family is, however, too blue-shifted for in vivo applications 
beyond virtually transparent organisms18 due to strong background absorption by 
endogenous chromophores at visible wavelengths (Fig. 1a). Unfortunately, the GFP-
like red-shifted fluorescent proteins exhibit limited PA signal generation efficiency 
and photostability.19 The development of phytochrome-based NIR fluorescent 
proteins have begun to overcome these limitations20,21 as they display a relatively low 
fluorescence quantum yield, making them ideal for PAI. Phytochromes are 
photosensory receptors that absorb light when they covalently bind a linear 
tetrapyrrole chromophore, such as biliverdin. Since biliverdin is an intermediate of 
normal mammalian heme metabolism, phytochromes are promising candidates as 
PAI genetic reporters for in vivo imaging. The first example in this class was iRFP, 
which can be excited at ~690 nm and shows good photo- and thermo-dynamic 
stability in vivo.21 More recently, differential imaging of the on / off states in the 
reversibly switchable phytochrome BphP1 has been demonstrated. Excitation of the 
biliverdin-BphP1 complex with light in the range of 730-790 nm triggers the bound 
biliverdin to switch from trans to cis conformation (Fig. 2b), causing a change in the 
absorption spectrum towards 630-690 nm.22 The photoconversion was shown to 
reduce the impact of background signals (Fig. 2c), improve detection sensitivity and 
increase penetration depth. Reversibly switchable phytochromes may therefore play 
a significant role in future preclinical research studies, for example, in localizing 
tumor development in transgenic mouse models in deep tissue. 
More widely explored transgenic approaches for PAI are based on enzymatic 
reporter genes. Here, the genetic product is an enzyme that produces a 
chromophore or its precursor. Enzymatic reporter genes can amplify signals as one 
enzyme can interact with many substrates. LacZ is a bacterial gene that encodes the 
enzyme β-galactosidase, which catalyzes the hydrolysis of lactose into galactose and 
glucose. For PAI, a lactose-like substrate, 5-bromo-4-chloro-3-indolyl-β-D-
galactoside (X-gal), is added.23 X-gal is transparent but upon metabolism a stable 
dark-blue product emerges. Dual-wavelength PAI can detect tumor cells expressing 
lacZ up to 5 cm depth with high resolution.23 The lacZ-reporter gene system is 
limited, however, as X-gal must be locally administered and the metabolic product 
shows poor clearance. The tyrosinase-reporter gene system (Fig. 2d,e) introduces 
the key enzyme in melanin synthesis into non-melanogenic cells, hence does not 
require an exogenously administered substrate.24 Although the relatively featureless 
absorption spectrum of melanin (Fig. 1a) could make it hard to distinguish from 
intrinsic signals, in vitro and in vivo PAI of tyrosinase-expressing cells has shown 
high sensitivity24,25 and inducible systems can address potential toxicity concerns.26 
Despite their potential for signal amplification, the enzymatic reporter systems are 
generally less desirable due to their lack of product specificity, as well as 
dependence on metabolic activity of the cells and substrate availability, which limits 
quantification.    
  
 
3. Exogenous contrast agent considerations for molecular PAI  
 
To perform molecular imaging, we create a contrast agent composed of a 
signaling compound, which produces the signal for imaging, and a targeting moiety 
that enables the readout of a specific biological process of interest (summarized in 
Fig. 3).  
 
3.1. Photophysical properties: signaling compounds  
 
The ideal signaling compound, which is the substance or label that provides 
the PAI signal, needs to exhibit the following characteristics: high molar extinction 
coefficient (Fig. 4), to maximize the amount of light absorbed; sharply peaked 
characteristic absorption spectrum, to ensure unambiguous identification by spectral 
unmixing even at low molar concentrations (see Supplementary Note 1); peak 
absorption in the NIR window (620 – 950 nm), to maximize penetration depth by 
avoiding the strong absorption of intrinsic chromophores (Fig. 1a); high photostability, 
to ensure that spectral features are not changed by light irradiation; low quantum 
yield, to maximize the non-radiative conversion of light energy to heat; and efficient 
conversion of heat energy to stress2, to produce acoustic waves. 
Signaling compounds that begin to fulfill the above criteria and can be 
sensitively detected using PAI are now available. These fall into three broad classes: 
small molecule dyes; metallic or semiconducting nanostructures; and organic 
nanostructures (Fig. 3). The resulting contrast agents (signaling compound + 
targeting moiety) must also overcome physiological barriers to reach the target, while 
ensuring biocompatibility for in vivo imaging, as discussed in the following section.  
 
3.2. Biological properties: targeting and biocompatibility  
 
The targeted molecular imaging contrast agent must overcome circulatory 
and cellular barriers (Fig. 5). Initially, the interaction of the contrast agent in the 
bloodstream must be carefully considered. For example, it is now clear that due to 
their high surface free energy, nanoparticles rapidly (within < 30 s) adsorb 
biomolecules when in contact with biofluids.27,28 The resulting ‘protein-corona’ is 
highly complex and functionally diverse, varying significantly between different 
nanoparticles.27 The presence of a protein-corona influences immune response and 
target binding28,29, which has led some investigators to suggest biological responses 
to nanoparticles in vivo reflect the nature of the adsorbed layer rather than the 
nanoparticle itself28. 
Assuming we can characterize the nature of the contrast agent interactions 
with the bloodstream27,28 the next stage is to pass out of the circulatory system. To 
extravasate, a maximum size limit of typically < 10 nm is necessary, although for 
applications in cancer, contrast agents of up to 100 nm have been found to pass 
through the leaky and immature vasculature30. Once in the tissue interstitium, 
passing the cellular barrier can be achieved by active targeting, for example to cell 
surface receptors31, transporters32, metabolic enzymes33 or biochemical processes34, 
or by relying on passive uptake through diffusion or endocytosis.  
 To facilitate active targeting, the biological target should be (over)expressed 
at a very early stage of the disease and found at low levels in off-target tissues. 
Structures that can be used to achieve active targeting include small molecules, 
peptides and adhirons35, affibodies36, aptamers37 and proteins; these are illustrated 
and reviewed in Figure 3. In particular, consideration must be given to 
biocompatibility, which refers here to minimizing toxicity (e.g. according to required 
administration route and dose) and immune response (e.g. by reducing accumulation 
in non-targeted tissue), as well as optimizing target tissue penetration and elimination 
from the circulatory system.  
For example, using small molecules for targeting enables the contrast agent 
to pass physiological barriers easily due to their small size (< 1 nm) and clear rapidly 
through the kidneys, which reduces off-target accumulation and optimizes 
biocompatibility. Conversely, although proteins (e.g. monoclonal antibodies) show 
high target affinity and specificity, and thus display little cross-reactivity with healthy 
tissues, their larger size results in poorer tissue penetration and clearance, and 
immunogenicity is possible, resulting in poorer biocompatibility. Antibody fragments, 
such as diabodies, are now being developed to address these challenges, since they 
are smaller in size but retain high affinity and selectivity.36,38 
As noted above, for cancer research, the hyperpermeability of tumor 
vasculature combined with the lack of an intact lymphatic drainage may lead to 
‘enhanced permeability and retention’ (EPR) of contrast agents of up to ~100 nm 
inside the tumor tissue without the need for targeting ligands.39 ‘Passive’ targeting 
based on the EPR has been demonstrated extensively in mice (see Supplementary 
Tables) and recently the first studies have begun to emerge in humans40. This 
passive approach can be applied to aid tumor localization. Larger entities (> 100 nm) 
are typically not accumulated and will be cleared through the reticuloendothelial 
system.30 From the perspective of molecular PAI, however, passive targeting 
confounds attempts to perform targeted molecular imaging, as uptake is not specific 
to a biological process hence should be avoided as far as possible by contrast agent 
design.  	  
 
  
4. Signaling compounds for molecular PAI 
 
A catalogue of exogenous contrast agent studies using PAI for the different 
classes of signaling compounds can be found in Tables S1-S4 and associated 
references. Figure 4 enables direct comparison of two critical parameters for the 
ideal signaling compound: the specific extinction coefficients and peak absorption 
wavelengths for the different classes. While small molecule dyes are generally 
commercially available, this is not often the case for nanostructures, so we refer the 
reader to Supplementary Note 2 for further information regarding common chemical 
synthesis routes for each class of nanostructure reviewed here. 
 
4.1. Small molecule optical dyes 
 
Small molecule optical dyes (Table S1) have optimal biocompatibility (good 
tissue penetration and rapid clearance) compared to all other molecular PAI contrast 
agent classes due to their small size (<2 nm). However, they also possess the 
poorest molar extinction coefficient and often exhibit relatively low photoacoustic 
generation efficiency and photostability. The chemical basis of these dyes is a series 
of conjugated double-bonds and/or (mostly aromatic) ring systems. In these highly 
conjugated structures, electrons are delocalized meaning less energy is needed for 
excitation. The well-defined energy gap between ground and excited states results in 
a distinct, albeit relatively broad, absorption peak (Fig. S1). Relaxation of the excited 
electrons can occur in radiative (fluorescence or bioluminescence) or non-radiative 
processes, dependent on the lifetime and electronic configuration of the excited 
states (Fig. 6a).41 For PAI, a large non-radiative relaxation is required so the 
quantum yield (referring to fluorescence emission) should be as low as possible.  
The first main class of NIR dyes used for PAI is the heptamethine cyanine 
dyes. They comprise two aromatic nitrogen-containing heterocycles linked by a 
heptamethine chain and their synthesis is well established.42,43 For example, 
indocyanine green (ICG) is an FDA approved dye with low toxicity. High 
hydrophobicity results in high plasma protein binding, hence it has been used in the 
clinic for over 35 years as a blood flow contrast agent.44 It has an absorption 
maximum at 780 nm (in aqueous solution) and a relatively low quantum yield for 
fluorescence (0.027 in aqueous solution) yielding PA signal.45 While ICG has been 
used as a perfusion marker in PAI for functional imaging5, the inherent 
hydrophobicity results in significant variations in the optical properties dependent on 
the concentration and environment (Fig. 6b)46 and targeting chemistry is difficult, 
meaning unmodified ICG is not ideal for molecular PAI.47,48 There is the prospect of 
addressing these limitations via modifications, such as the integration of a 
cyclohexenyl ring in the methine linker, which can increase photostability and enable 
further chemical modifications for targeting.43   
Squaraines are the second main class of NIR dyes that could be employed 
for molecular PAI. They are characterized by an electron deficient central 4-
membered ring often conjugated to two electron-donating groups to generate a 
donor-acceptor-donor form, which increases the delocalization of the electrons. The 
optical properties can be tuned by varying donor strengths to produce sharp 
absorption bands in the NIR range.49 Despite good optical properties and 
photostability, squaraines are often limited by insolubility, aggregation and chemical 
reactivity.50,51 In PAI they have only been used in conjunction with phospholipids, 
albumin or polymers (see Section 4.2.3) owing to poor solubility.52–54  
The two water soluble, FDA-approved azo dyes, methylene blue (MB) and 
Evans blue (EB), with absorption peaks at 664 nm (MB) and 620 nm (EB), have also 
been used for PAI but are limited at depth as their absorption peak is at lower end of 
the NIR range.55,56 Characteristic for MB is its long triplet state lifetime and a high 
quantum yield for triplet state transition, which can be used for PA lifetime imaging.55 
Although most NIR dyes are benign in vivo, MB can cause photodamage under 
intense irradiation and chemical side effects due to reactions with cellular molecules 
(e.g. NADH, FADH),57 making it less desirable. 
Given the existing FDA approval of ICG, MB and EB as blood flow agents, 
they were quickly applied in cancer research studies using PAI for identification of 
the closest lymph node in the drainage path from a tumor58–60, the sentinel lymph 
node (SLN). This process is crucial in TNM clinical cancer staging. However, as an 
example of the limitations of passive targeting, SLN identification with dye molecules 
has shown a relatively high false positive rate.61 
Most small molecule dyes must be actively targeted to gain specificity. A 
common target for detection and characterization of solid tumors in preclinical 
research is the cell surface epidermal growth factor receptor (EGFR). EGFR is 
frequently overexpressed in solid tumors, including breast and pancreatic tumors, 
contributing to uncontrolled cell proliferation. Several successful targeted cancer 
therapies (e.g. cetuximab, gefitinib, erlotinib) function by inhibiting EGFR62,63, hence 
imaging the expression of EGFR within a tumor could help select patients for such 
therapy and monitor their response. Hudson et al explored the potential of molecular 
PAI for this application in an orthotopic mouse model of pancreatic cancer (depths >5 
mm) by conjugating the epidermal growth factor (EGF) protein to the NIR dye CF-
750 (Fig. 6c).64 The absorption spectrum of CF-750 was not significantly altered by 
the bioconjugation to EGF and the probe signal could be clearly distinguished from 
background by multi-wavelength PAI, providing a non-invasive readout of EGFR 
expression. Importantly, there was no noted toxicity.  
4.2. Nanostructures 
 
Nanoparticles (NPs) embody the largest class of contrast agents for 
molecular PAI. They possess high chemical, physical and biochemical flexibility, as 
well as significantly increased molar extinction coefficients compared to small 
molecule dyes. NPs exist in different materials, shapes and sizes (< 1000 nm, 
usually ~10-100 nm), and have tunable surface properties, reactivity and optical 
characteristics. Their large surface area enables signal amplification as the large 
number of targeting moieties that can be attached per particle increases the target-
binding probability. However, due to their larger size, NPs often accumulate in the 
reticuloendothelial system for long time periods, yielding poorer biocompatibility. 
Furthermore, the reproducibility, purification, and quantification of homogeneous NP 
preparations remains challenging.65 Details of the synthesis routes that are currently 
used to define optical properties for all nanostructures (metallic, semiconducting and 
polymer) are given in Supplementary Note 2, while reports of alternative 
nanomaterials including perfluorocarbon, iron oxide and copper sulfide are detailed in 
Supplementary Note 3.  
4.2.1. Gold 
 
The main focus of research into metallic nanoparticles for molecular PAI has 
been on gold, owing to its unique optical and physicochemical properties, relatively 
inert nature, and prior use in humans (for example, in treatment of rheumatoid 
arthritis and dental fillings). In addition, gold forms strong gold-thiolate bonds that 
enable covalent surface modifications for optimizing biocompatibility (e.g. 
poly(ethylene glycol) (PEG) functionalization)66, stability (e.g. silica encapsulation)67 
and active targeting (conjugation to ligands as in Fig. 3). 
The optical properties of GNPs arise from the ‘localized surface plasmon 
resonance’ (LSPR) phenomenon. The conduction electrons of a GNP oscillate 
relative to the atomic core when exposed to light of an appropriate wavelength (Fig. 
7a). This state is referred to as plasmon.68 Plasmons convert a significant part of the 
oscillation energy into heat detectable with PAI. The key advantage of GNP for PAI 
signal generation is that they essentially act as a macroscopic dipole, leading to an 
extinction coefficient several orders of magnitude higher (Fig. 4) than small molecule 
dyes (extinction scales ~ volume^3).69  
The frequency of the LSPR determines the peak absorption wavelength of the 
GNP, which can be tuned based on: size (surface-to-volume ratio); polarization 
modes; edge / vertex number and ‘sharpness’ of the GNP. Therefore, in addition to 
spheres, a wide range of GNP shapes, including stars, tripods, plates and prisms 
have emerged (Table S2). One key example of tuning is found in gold nanorods 
(GNRs), whose intense and narrow LSPR absorption bands in the NIR are tuned by 
varying their aspect ratio (Fig. 7b, Supplementary Note 2.1). Under laser illumination 
for PAI, larger GNRs may not be thermodynamically stable70 and can collapse to 
spherical GNPs or fragment / sublime. Silica encapsulation has been found to 
improve photostability71 by increasing thermal conductivity to the surrounding 
medium, which also increases PA conversion efficiency.67,72 A second key example is 
the use of hollow gold nanostructures, such as gold nanocages (GNCs) and gold 
nanoshells (GNSs) that can encapsulate cargo such as drugs within their porous 
walls for theranostic purposes (see Section 5). The LSPR frequency can be 
conveniently tuned not only based on size but also on shell thickness (thinner = red 
shift) (Fig. 7c).73,74 These simple methods for tuning the characteristic spectral shape 
and peak wavelength are highly advantageous for molecular PAI. 
Active targeting of GNRs has been demonstrated through antibody 
conjugation (Table S2) although it is more challenging than for small molecule dyes 
due to the larger size of the GNR relative to physiological barriers. Due to their 
relatively narrow spectrum, GNRs tuned to absorb at a range of different peak 
wavelengths can be conjugated to multiple targets, which has enabled multiplexed 
characterization of tumor EGFR and human epidermal growth factor receptor 2 
(HER2) expression, allowing characterization of heterogeneous tumors11 and 
potentially enabling specific tracking of combination therapies.  
In addition to cancer cell receptors, an alternative approach for tumor 
targeting is specific imaging of the angiogenic tumor vasculature (in contrast to 
quiescent surrounding vessels) by targeting αvβ3 integrin, which is overexpressed on 
angiogenic blood vessels. Targeting the vasculature removes the physiological 
barrier of extravasation in molecular imaging. The tripeptide arginine-glycine-aspartic 
acid (RGD) and its derivatives are widely used targeting moieties. All reports to date 
use a bifunctional PEG linker to conjugate the GNP with the RGD derivative (Table 
S2). Studies with larger RGD-modified GNPs suffer from high accumulation in the 
reticuloendothelial system and slow tumor accumulation of at least 6 h.31,75 This is 
unfavorable in terms of biocompatibility, as it renders the reticuloendothelial system 
organs prone to, for example, oxidative damage via free radical formation.76 These 
limitations were recently overcome using small gold tripods (< 20 nm) conjugated to 
the RGD derivative cyclic Arg-Gly-Asp-D-Phe-Cys via a PEG linker (Fig. 7d, e), 
obtained in high yield with narrow size / shape distributions and, due to their PEG-
coating, excellent stability.77 PAI results were verified with 64Cu PET. Encouragingly, 
RGD-gold tripods showed rapid tumor accumulation within 2 hours (subcutaneous 
U87MG in mouse) without systemic toxicity. While preclinical GNP studies generally 
show low acute toxicity, in vivo biocompatibility needs to be more systematically 
addressed through longer term toxicity studies for each nanostructure to establish 
the impact of these non-biodegradable NPs. 
 
4.2.2. Carbon  
 
Carbon forms different allotropic structures: carbon nanotubes, graphene-
based nanomaterials and nanodiamonds. All three classes can be synthesized to 
possess an intrinsic absorption in the NIR range (Fig. 8, Fig. S2, Supplementary 
Note 2.2) and thus play an important role for PAI (Table S3). Despite possessing a 
lower molar extinction coefficient than gold, carbon nanoparticles (CNPs) hold 
significant potential for molecular PAI due to their flexibility of synthesis and 
functionalization (Supplementary Note 2.2). Of particular interest is the wide variety 
of covalent78–81 as well as non-covalent modifications with small molecules (dyes82, 
drugs83, surfactants84), polymers82 and biomolecules85 that can be used for: targeting; 
increased solubility and stability86; improved signaling properties87, increased 
specificity82; or for theranostic approaches88. The absorption spectra of CNPs tend to 
be relatively broad in the NIR range, presenting a challenge for spectral unmixing in 
molecular PAI, but the attachment of NIR dyes can circumvent this limitation (Fig. 
S3).  
  The majority of molecular PAI studies using carbon have been performed 
using single-walled carbon nanotubes (SWNT). SWNTs can be visualized as 
cylindrically rolled-up graphene sheets with diameters of 1-3 nm and lengths up to 
centimeters (Fig. 8a).89 Semiconducting SWNT exhibit numerous optical absorption 
peaks of relatively similar magnitude (Fig. 8b,c). The absorption peaks are defined by 
narrow energy ranges where many electronic states are available (referred to as van 
Hoff singularities, Fig. 8b). The electronic, and thus optical, properties are tunable by 
changing the tube structure, for example, diameter and chirality. The bandgap 
generally varies inversely with the diameter, but many open questions remain 
regarding the complex photophysics of SWNTs.90,91 
 Molecular targeting of the αvβ3 integrin for angiogenesis imaging has been 
achieved in multiple studies of CNPs using RGD-peptides attached to SWNT.82,92–94 
De la Zerda et al conjugated RGD peptides through PEG grafted phospholipids to 
SWNT. In vivo evaluation found a strong PAI signal in the tumor for SWNT-RGD 
compared to only weak signals (via passive EPR uptake) for non-targeted SWNTs.92 
Attachment of NIR dyes to the surface of the nanotubes achieved over 100-times 
higher PA contrast and sub-nanomolar sensitivities in mice compared to plain 
SWNT.82,94 However, the extent to which the improved sensitivity was due to 
synergistic quenching effects between the dyes themselves or between the dyes and 
the SWNT was not established. In addition, photobleaching can occur due to the 
instability of the dyes associated with these constructs.  
SWNTs have also been specifically targeted to tumors overexpressing the 
cell surface glycoprotein CD44, which has been implicated in many tumor hallmark 
processes including cell proliferation and migration. Targeting of CD44 has been 
considered for both diagnosis and therapy of the disease.95 Coating SWNT with a 
hyaluronic acid-based biosurfactant acts as targeting moiety to CD44. The coating is 
degraded by enzymes (hyaluronidases) overexpressed in cancer cells. Further 
labeling of the hyaluronic acid-unit with a fluorescent dye has been used to provide 
validation of the selective CD44 receptor uptake using PAI and fluorescence imaging 
(Fig. 8d, e)86 illustrating controlled SWNT delivery. 
 Several studies have reported cytotoxicity and inflammatory potential of 
SWNTs96,97 that can be significantly reduced by functionalization.98,99 On the contrary, 
emerging evidence suggests that nanodiamonds exhibit high 
biocompatibility100,101,102, which makes them a promising new molecular PAI contrast 
agent. As for GNPs, the biological impact of CNPs is dependent on the surface 
modification, size and synthesis method.103 Significant future effort will need to be 
invested to better understand CNP photophysics and biocompatibility, in order that 
their highly flexible functionalization and tunable optical properties can be fully 
exploited for molecular PAI. 
4.2.3. Organic Nanostructures 
	  
An exciting recent development in molecular PAI is the use of polymer 
nanoparticles and encapsulations (Table S4). They have a high structural and 
functional flexibility (composition, shape, charge, size) and for molecular PAI act: a) 
directly as signaling compounds; b) to enhance the biocompatibility of other signaling 
compounds; or c) as a foundation for activatable imaging probes. The most popular 
organic polymer structures used for PAI contain either conjugated polymers or 
porphyrin related units, such that they directly absorb light. Their molar extinction 
coefficient sits between the small molecule dyes and GNPs (Fig. 4), and while their 
absorption spectra may be broad (Fig. 9a), they usually exhibit a well-defined 
absorption peak in the NIR and are also relatively photostable. Furthermore, the 
chemically and physically stable polymeric platform provides the opportunity to attach 
specific targeting and therapeutic moieties (see Supplementary Note 2.3) and may 
yield favorable biocompatibility, although this has yet to be established.  
 Polymer nanoparticles come in many different flavors. Conjugated polymers 
(CP) are macromolecular structures with a highly delocalized conjugated backbone 
(Fig. S4a). In contrast to small molecule NIR dyes, the conjugated system is spread 
through the entire polymer backbone and the polymers are densely packed into NPs 
yielding high absorptivity and photostability. The optical properties (strongly 
dependent on the conjugated core) can be tuned by adopting different backbone 
structures, combining different conjugated polymers and controlling aggregation and 
surface functionalization.104–106 As an example, polypyrrole NPs are advantageous for 
PAI due to intense NIR absorption, high photothermal conversion efficiency and good 
biocompatibility even though their absorption spectrum is relatively featureless.107 
They can be well dispersed in aqueous solution and biocompatible due to their small 
size (<50 nm) and hydrophilic surface coating.107 However, they lack functional 
groups for surface modification, so alternative CPs that can be enriched with 
functional units are being developed.108,109 These alternative CPNPs are 
characterized by high photostability and an alternating electron donor-acceptor 
structure, which increases the delocalization of the electrons in the conjugated 
system, shifting the absorption spectrum towards longer wavelengths (Fig. S4b). 
Compared with SWNTs and GNRs they also have been shown to yield 4-fold higher 
PAI signal in vivo on a per mass basis, but lower than the GNRs when compared on 
a molar basis.109 They have also facilitated the development of a ‘smart’ contrast 
agent (see Section 5) for in vivo real-time imaging of reactive oxygen species.109  
Alternatives to synthetic CPs are the naturally occurring porphyrins, aromatic 
macrocycles from heme and chlorophylls containing four pyrrolic units linked by 
methane (Fig. S4a). The chemical reactivity of the porphyrin macrocycle offers 
architectural flexibility, which permits tuning of the optical properties (Fig. S4b). As 
with uncoated CPNPs, porphyrins are extremely insoluble. Lovell et al overcame this 
challenge by conjugating porphyrin to a phospholipid, which resulted in self-
assembled porphysomes with a bilayer structure.110 The porphyrin molecules inside 
the porphysome create J-aggregates, red-shifting the absorption peak (Fig. S4b), 
and causing fluorescence quenching to yield a strong NIR PA signal.111,110 The 
porphyrin-lipid shell was also used for encapsulation of carboxyfluorescein, 
doxorubicin110 or fluorinated gases enabling multimodal PAI, US and fluorescence 
imaging.112,113 As natural products, poryphyrins and porphysomes would be expected 
to show high biocompatibility, but due to their relative immaturity as contrast agents, 
this has yet to be established in vivo.   
Other polymers lacking intrinsic optical absorption but showing favorable 
biocompatibility can incorporate added signaling compounds through micellar or 
vesicular structures. Liposomes have already been used in the clinic as drug delivery 
vehicles, providing a promising route towards clinical application.114 Gold 
nanobeacons are formed from small GNPs (2-4nm) trapped within synthetic or 
natural amphilines, forming NPs 60 – 260 nm in size.115,116  Advantages of such 
formulations include improved photo-stability, biocompatibility, signal intensity and 
targeting ability, relative to the signaling compound alone. Disadvantages include the 
presently limited knowledge of how polymer NP structure and local signaling 
compound concentration influences PA signal generation, as well as the larger size 
of the encapsulation. 
Despite their early stage of development, polymers and encapsulations have 
been demonstrated in numerous passive targeting applications: imaging mouse brain 
vasculature107,117 and tumor sentinel lymph node identification109,118,110 as well as  
primary tumor characterization119–121. Conjugation of polypyrrole NPs to folic acid has 
recently been shown to actively target folate receptor positive  (FR+ve) MCF-7 
breast cancer xenografts (Fig. 9b, c). Biocompatibility was assessed only in cells in 
vitro; studies in vivo were limited to evaluating biodistribution, which showed the 
expected involvement of the reticuloendothelial system in contrast agent 
clearance.108 Wang et al exploited the same target with poly(D,L-lactide-co-glycolide) 
(PLGA) lipid NP doped with ICG. Both PLGA and ICG are FDA approved and the 
fabricated NPs showed good stability, high folate-receptor targeting efficiency and 
good PA signal in vitro and in vivo in the same model.122 This shows promise for 
clinical translation, although it should be cautioned that FDA approval of the 
individual elements would not necessarily speed up approval of the newly 
synthesized product.  
5. Emerging concepts in molecular PAI  
 
Smart (or ‘activatable’) contrast agents elicit a prescribed signal change, such 
as a shift in the peak absorption wavelength, in response to a biological stimulus of 
interest. As well as increasing the range of possible molecular imaging targets, a key 
advantage of smart contrast agents is that they minimize the influence of the 
background signal from endogenous chromophores such as hemoglobin, hence 
offering a potential for high sensitivity of detection. The dynamic response of smart 
contrast agents also facilitates the study of processes such as enzymatic activity in 
real-time. Although relatively few examples exist so far for PAI, targeting proteases 
including matrix metalloprotease10 and furin33 has proven popular. Proteases are 
implicated in a range of disease processes, including tumor invasion and metastasis. 
In ‘smart’ contrast agents, the protease substrate (a short peptide) links a quencher 
(BHQ3) with either a fluorophore (Alexa750)10 or NP (CuS)123. PA images acquired at 
the peak wavelengths of the two absorbers both show strong signals before the 
contrast agent reaches the target. Inside the tumor microenvironment, proteases 
cleave the linker, leaving one absorber that is targeted to reside in the tumor while 
the other absorber is cleared. Only one absorption peak is thus detected after 
cleavage, yielding a highly specific imaging approach to quantify protease activity 
non-invasively. Undesirable toxicity in off-target tissues with high physiological 
protease levels has yet to be assessed. 
Multifunctional contrast agents can enable imaging of targets with different 
imaging modalities simultaneously (‘multi-modality’) or also deliver therapeutics 
(‘theranostic’). Using multi-modality contrast agents it is possible to image the same 
target with two or more approaches (overcoming weaknesses of each modality) or to 
readout multiple targets, building a more complete picture of the underlying 
biochemistry. Molecular imaging modalities can differ in sensitivity up to 6 orders of 
magnitude124 requiring a difficult compromise to satisfy the concentration 
requirements for each modality. While PAI has been combined with PET77 and/or 
MRI125,126 for whole body imaging to determine contrast agent biocompatibility, its 
natural partners are ultrasound and fluorescence imaging due to the acoustic 
detection and optical excitation paths. Several PA-contrast enhanced US contrast 
agents are available. Small molecule dyes used for PAI are also fluorescent. The 
motivation for combined fluorescence imaging is clear for surgical interventions: the 
increased depth penetration of PAI enables identification of the target with high 
spatial resolution, while real-time intraoperative tumor resection guidance is easily 
provided by fluorescence detection, avoiding the need for acoustic coupling of the 
PAI probe.127  
 Theranostic approaches link the disease diagnosis directly to therapy. The 
final aim is to create a safer, more efficient and tailored treatment aligned with the 
concept of precision medicine. In vivo use of theranostic agents will help to better 
quantify target-specific delivery of the drug and controlled release128 However, 
defining the distribution and effect of the therapeutic after release from the conjugate 
or carrier remains challenging, as do the opposing requirements of imaging agents 
and therapeutics including dosage and accumulation time.129 A key example of 
theranostics with PAI is the use of photothermal therapy and photoactivated drug 
release in cancer. Exploiting the strong optical absorption and thermal conductivity of 
gold125, carbon130 and CuS128,131 nanostructures, initial reports have shown promise 
but further work is needed to assess the true benefit of such combinations.  
 
6. Outlook: Promise and future challenges  
 
Molecular PAI is an exciting new modality that enables simultaneous imaging 
of endogenous chromophores in target cells and exogenous contrast agents that 
provide visualization of dynamic biological processes. In addition to using non-
ionizing radiation and imaging in real-time with high spatial resolution, the technology 
also has the potential for relatively low cost implementations. While a broad range of 
application areas for molecular PAI have been identified, including oncology, 
neuroscience and cardiovascular diseases, basic research studies and preliminary 
clinical trials have focused primarily thus far on detection, staging and therapeutic 
monitoring in cancer.  
 
6.1 How do we identify the most suitable contrast agent for a given molecular 
PAI application?  
 
As reviewed in Section 3, development of a new contrast agent for molecular PAI 
requires consideration of both photophysical (optical and thermodynamic) and 
biological properties. Here we summarize these properties for each reviewed 
contrast agent class. 
 
6.1.1 Small molecule dyes 
 
With respect to the photophysical properties of the signaling compound, dyes 
typically exhibit a relatively low molar extinction coefficient (<3x105 M-1 cm-1). They 
can also lack photostability or solubility and tend to aggregate. This intrinsic 
hydrophobic conjugated structure can lead to concentration- and environment-
dependent spectral changes, which may make them difficult to detect in vivo. It is 
possible to address some of these challenges chemically, by attaching hydrophilic 
groups, introducing triplet-state quenchers132 and integrating stabilizing groups133. 
Additionally, variations in the chemical design, such as varying the size of the 
conjugated system, attaching electron donating / withdrawing groups, allow tailoring 
of the spectral range. Their chemical flexibility also facilitates the creation of ‘smart’ 
contrast agents, which can in part compensate for their low molar extinction 
coefficient by minimizing the influence of the background signal from endogenous 
chromophores. 
For molecular imaging, when combined with small targeting moieties, dyes 
can easily pass physiological barriers and be actively transported into cells. They are 
rapidly cleared through the kidneys, which leads to a short blood half-life, minimal off 
target accumulation and hence favorable biocompatibility. The short half-life, while 
favorable for imaging perfusion, can present a challenge for molecular imaging 
studies as it limits the time for which the dye will circulate and hence accumulation at 
the target site.  
On balance, in spite of their limitations, small molecule dyes remain good 
candidates for molecular PAI in the preclinical study of extravascular targets due to 
their small size, favorable biocompatibility and the ability to engineer ‘smart’ 
responses. 
 
6.1.2 Gold nanoparticles 
 
GNPs show the highest extinction coefficient in the NIR range and high PA 
conversion efficiency. Their narrow absorption spectrum can be tailored by tuning the 
LSPR using the size, thickness, edge number and sharpness of the GNP. These 
properties, along with surface coatings, can also be used to maximize photostability. 
GNPs therefore possess the most flexible photophysical properties of the 
compounds reviewed. Furthermore, easy and stable functionalization of GNPs can 
be made via gold-thiolate bonds, making them suitable for attachment of a range of 
targeting moieties and further signaling compounds for multimodal imaging. Their 
associated spectral flexibility means GNPs are highly suitable for multiplexed 
imaging of different targets within the same tissue. 
In diseases that exhibit a leaky vasculature, like cancer, GNPs can be 
accumulated via the EPR effect (discussed in Section 3). Active targeting of GNPs to 
cell surface receptors has only been demonstrated in a limited number of cancer-
related applications; it remains to be seen whether the use of GNPs in reaching 
extravascular targets generalizes across disease types and to other applications. 
Interaction of the GNPs reviewed here within the vascular and tissue compartments 
depends on their size, shape, charge and synthesis route. Hence, despite prior use 
of colloidal gold for therapeutic applications, for longitudinal monitoring studies 
requiring repeated contrast agent administration, biocompatibility in vivo may still 
present challenges since gold is not biodegradable. 
 
6.1.3 Carbon nanoparticles 
 
High photostability along with versatile methods of surface modification and 
functionalization make CNPs attractive for molecular PAI. CNPs come in three 
flavors: graphene nanosheets are zero band gap semiconductor with broad and flat 
absorption spectrum; semiconducting SWNT have a more specific absorption profile 
modified by tube diameter and chirality; carbon nanodiamonds can have high and 
specific NIR absorption depending on vacancies in the diamond crystal lattice. The 
photophysical properties of CNPs are generally limited by their relatively broadband 
absorption profile as well as low molar extinction coefficient (similar to dyes). It is 
possible, however, to address these limitations at least in part by conjugation of small 
molecule dyes to the SWNT and tuning of nanodiamond vacancies.  
Current evidence as to the biocompatibility of CNPs is relatively limited but 
suggests that size and shape play a role (as with GNPs). Nanodiamonds may be 
most promising for preclinical studies, as they appear to lack toxicity based on in vitro 
experiments. Systematic studies are required nonetheless to assess acute and long-
term toxicity in vivo. Should these prove promising, the flexible physicochemical 
properties make CNPs an attractive target for future contrast agents. 
 
6.1.4 Polymers and encapsulations 
 
Conjugated polymers and porphyrin-based nanostructures can provide strong 
optical absorption due to the presence of highly delocalized electrons in the 
conjugated system, which is higher than both small molecule dyes and CNPs 
reported to date. Changing the delocalization degree of these electrons through 
electron donating / withdrawing groups and the inter- and intra- chain interactions 
can influence their photophysical properties. 
The stable polymeric platform provides an opportunity to attach not only 
active targeting moieties but also drugs for theranostic applications and activatable 
functionalities for smart probes. Given that this class of contrast agents is relatively 
new, detailed biocompatibility studies are still lacking to prove their potential for in 
vivo application. However, water-soluble, organic polymeric structures such as 
liposomes (that lack intrinsic optical absorption but are already clinically approved) 
have been combined with other signaling compounds to create a polymeric contrast 
agent with known biocompatibility. 
Polymers and encapsulations represent a growing field in molecular PAI, with 
exciting potential for theranostics given their high functional flexibility. Further work to 
develop biocompatible platforms with even higher NIR absorption is expected to 
emerge in the coming years. 
 
6.2 How do we facilitate uptake of molecular PAI in basic research? 
 
Despite great progress in molecular PAI contrast agent development in recent 
years, several challenges must be overcome in order to facilitate uptake into basic 
research in the life sciences. It is crucial that the field recognize the need for 
standardized reporting of experimental approaches, for example, with regard to the 
measured photophysical properties. Publications should report in detail their 
calculations of extinction coefficients on both a ‘per mass’ and ‘per mole’ basis, along 
with independent measurements of both optical and photoacoustic absorption 
spectra as a function of concentration and solvent. Such data has a major impact on 
biocompatibility since detection sensitivity is intrinsically linked to dosing in vivo. 
Systematic studies to improve solubility, stability and specific targeting capability 
would be highly advantageous in this regard, as would reproducible, cost effective 
and scalable chemical syntheses and purification methods.  
With photophysical and chemical characteristics optimized, criteria related to 
targeting and biocompatibility must also be fulfilled. Relatively few studies have 
shown convincing evidence of active targeting, for which cellular controls (e.g. 
knockdowns) and physiological controls (e.g. blocking) are needed. The large size of 
nanostructures relative to physiological barriers may limit their application to 
intravascular targets for molecular imaging outside of cancer. Although the materials 
reviewed here are often claimed to be inert, biocompatibility appears to be strongly 
dependent on the nanostructure size, shape and synthesis method used in their 
preparation. Biological interactions, immunogenicity, stability, circulation and target 
tissue retention must therefore be well characterized to define the safety profile of the 
contrast agent on a case-by-case basis. Recent studies tend to consider in vivo 
biodistribution and in vitro toxicity but rarely combine both. Therefore, going forward, 
biocompatibility of different contrast agents has to be better evaluated at the cellular 
and organismal levels (both through blood sampling and tissue analysis) to identify 
potential acute and chronic inflammatory and toxicity effects.  
With biocompatibility concerns addressed, molecular PAI then has to achieve 
technical and biological validation before acceptance as a routine tool. Technical 
validation requires assessment of precision (repeatability / reproducibility) and 
accuracy (ability to relate the imaging signal to the abundance of chromophore). 
Although there have been significant efforts relating to accuracy of PAI134, there 
remains a paucity of data relating to precision. Biological validation of the sensitivity 
and specificity of the readout in relation to the target biological process should be 
made using in vivo models that recapitulate the human condition being studied. This 
review has revealed the near ubiquitous use of simple animal models, including 
subcutaneous tumors. Immunodeficient nude mice are also used routinely, which 
avoid the impact of skin melanin on optical absorption and minimize interactions with 
the immune system. While these systems provide an acceptable proof-of-concept, 
comparison between contrast agents would benefit from standardization (using 
published recommendations, e.g. by Dawidczyk et al135) with regard to the disease 
model, tumor sizes, time points and reported metrics. Translation of findings into 
transgenic mouse models on immune competent backgrounds (e.g. C57BL/6) will 
ultimately be needed for widespread uptake in preclinical research.  
The exogenous contrast agents described here are still in the early stages of 
exploration. Opposing the current trend towards vast increases in the number of 
different signaling compounds available, we believe it is crucial to better understand 
the photophysical and biological properties of the classes that have already been 
reported. Lessons learned from other areas of molecular imaging indicate that 
focusing efforts on contrast agents that prove successful in more rigorous studies of 
biocompatibility and biological validation using realistic animal models of disease can 
help to accelerate widespread application. Future studies must also include 
comparisons to gold standards, either in vivo with other imaging modalities or ex vivo 
with histology. While challenging, if successful, these studies will likely aid the uptake 
of PAI as a tool in preclinical cancer biology and hence facilitate rapid clinical 
translation of PAI as a localized molecular imaging modality for personalized patient 
management. 
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Figure 1. Photoacoustic imaging of endogenous chromophores.  
a) Absorption spectra of the main endogenous light absorbing components. λ=584 
nm and λ=797 nm are the isosbestic wavelengths where HbO2 and Hb have identical 
molar extinction coefficients, enabling measurement of Hbtotal. Oxyhemoglobin 
(HbO2), red line (150 gl-1); deoxyhemoglobin (Hb), blue line (150 gl-1); water, black 
line136 (80% by volume in tissue); lipid, yellow lines137,138 (20% by volume in tissue); 
melanin, brown line (µa corresponds to that in skin); collagen, green line. 
b) The different configurations of the heme group before and after oxygen binding 
leading to the characteristic changes in the absorption spectrum.  
c) PAI (λ=640 nm) of tumor vasculature showing the effect of the vascular disrupting 
agent OXi4503.6 
Data in (a) taken from http://omlc.ogi.edu/spectra/  
a) b) 
c) 
 	  
Figure 2. Photoacoustic imaging of genetically encoded chromophores. 
a) Simplified schematic demonstration of a general enzymatic reporter gene 
construct.  
b) Photoswitching chemistry of a Biliverdin chromophore from the Pfr state to the Pr 
state, and vice versa, induced by NIR (~730 – 790 nm) and far-red (~630 – 690 nm) 
light illumination, respectively.22  
c) Deep PA computed tomography of mouse brain U87 tumor expressing BphP1, 
with the surrounding vasculature show in grayscale. The tumor (in color) was ~3mm 
beneath the scalp surface.22 
d) Retroviral vector construct for stable transduction of cells for visualization of 
tyrosinase (Tyr) expression mammalian cells. (LTR: long terminal repeat, includes 
the promotor; SD: splice donor; ψ: viral packaging signal, which directs the 
incorporation of vector RNA into virions; SA: splice acceptor; IRES: internal ribosome 
entry sites).24  
e) Serial longitudinal in vivo PA images of stable transduced, Tyr-expressing K562 
cells after subcutaneous injection into the flank of a nude mouse, illustrating sensitive 
detection of produced melanin with depth resolution afforded by PAI (spatial 
resolution <100 µm at up to 10 mm depth).24 
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Figure 3. Assembly of molecular imaging contrast agents for PAI combining a 
signaling compound with a targeting ligand. Current strategies for the 
development of targeted contrast agents, are: the direct conjugation of signaling 
compounds with targeting ligands; encapsulation of signaling compounds (and 
targeting ligand) by nanostructures; or encapsulation (with targeting ligands) and 
synthesis of target-activatable signaling compounds. The targeting ligand and 
signaling compound should be compatible in their chemical, physical and biological 
properties. Examples of the relative advantages and disadvantages of each 
approach are indicated by +/-.32,33,126,139,140  
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Figure 4. Schematic overview of the reported extinction coefficients of a 
selection of signaling compounds used for PAI: 
Peptide-grafted nanodiamonds87; methylene blue141; IC7-1-Bu142; CDnir7143; 
IRDye800CW, ICG (http://www.spectra.arizona.edu/); SiNc144; gold nanospheres145; 
SWNTs109; SPN1109; gold nanostar146; porphysome110; gold nanorod147; gold 
nanopopcorn148; conjugated polymer NP109; cellulose NP119; gold nanocages149; PSS-
coated gold nanorods150; gold nanocubes151; and gold nanoshells152. (λ represents 
the peak absorption wavelength). 
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Figure 5. Physiological barriers encountered during molecular imaging.  
Design of contrast agents for molecular PAI must consider both circulatory and cellular 
barriers, as well as the active targeting of cell surface receptors, transporters, metabolic 
enzymes or biochemical processes to provide the molecular readout. 
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Figure 6. Optical properties of near infrared (NIR) small molecule dyes and application 
for imaging the extravascular target epidermal growth factor receptor (EGFR) in 
pancreatic cancer. 
a) General Jablonski diagram showing energetic transitions for a NIR dye after optical 
excitation. 
b) Example absorption spectra of ICG in water and plasma in different concentrations. The 
dye concentration and in vivo environment both significantly impact the spectral properties of 
small molecule dyes, which can be challenging for PAI studies (spectra data used from 
University of Arizona http://www.spectra.arizona.edu/)  
c) Multispectral optoacoustic tomography (MSOT) of pancreatic adenocarcinoma from a 
mouse at 7 days post implantation using EGF-CF-750 at 6 hours postinjection.64 	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Figure 7. Optical properties of gold nanoparticles (GNP) and application for imaging 
the intravascular target αvβ3 integrin in glioma. 
a) Localized surface plasmon resonance (LSPR) of spherical GNP and GNR: 
electromagnetic waves induce collective oscillation of the conduction electrons relative to the 
lattice of positive atomic cores (due to Coulomb interactions), which can be described as a 
bosonic quasiparticle, the plasmon. Plasmons can decay radiatively via re-emitting photons 
(scattering) or non-radiatively by e.g. transferring the energy to electrons leading to hot 
electron-hole pairs. The relaxation of the excited electrons leads to a partly conversion of the 
energy into heat, essential for PAI.153,154  
b) Surface plasmon absorption spectra of gold nanorods of different aspect ratios, showing 
the sensitivity of the strong longitudinal band (longitudinal LSPR, lLPSR) to the aspect ratios 
of the nanorods (tLSPR = transverse LSPR). In comparison to GNR, gold nanospheres (grey 
line) show one peak absorption in green spectral range. (modified from ref.155) 
c) Surface plasmon resonance frequency of gold nanoshells can be tuned towards the NIR 
range by varying the shell thickness relative to the core size.156 
d) PAI and ultrasound imaging of U87MG tumours in nude mice with intravenously injected 
αvβ3 integrin targeted gold tripods.
77 
e) Chemical structure and UV-Vis spectroscopic profile αvβ3 integrin targeted gold tripods.
77 
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Figure 8. Optical properties of carbon nanotubes and application for imaging the 
extravascular target CD44 receptor in head and neck squamous cell carcinoma. 
a) Schematic honeycomb structure of a single layer graphene sheet and structure of a 
semiconducting zigzag-single walled carbon nanotubes (SWNT) as well as a metallic 
armchair-SWNT. SWNT can be formed by rolling up the graphene sheet from lattice point 
(0,0) to (n,m) along a chiral (roll-up) vector; the vector's length indicates the 
circumference/diameter of the tube, the chiral angle (alpha) the tilt between the hexagonal 
lattice and that vector and thus the chirality. Depending on the nanotubes diameter and twist 
the SWNT can be metallic (red n,m numbers) or semiconducting (blue n,m numbers). 
b) Schematic illustration of the density of states (DOS) with respect to energy for 
semiconducting SWNT. (k = wavevector, S11/22 = first/second energy transition for 
semiconducting SWNT)  
c) UV-vis-NIR absorption spectra of SDS-suspended HiPco SWNT showing the S11 and S22 
regions. These spectra are of sodium dodecyl sulphate (SDS)- suspended HiPco SWNTs. 
Resolved peaks correspond to various (n, m) structures.157 
d) Schematic illustration of dye-labeled hyaluronic acid-5beta-cholanic acid (HAC) conjugate 
and its activation of fluorescence properties. HAC wraps the SWNT due to hydrophobic 
interactions with cholanic acid, while the hydrophilic backbone provides solubility. In the 
attached form the fluorescence of the dye is quenched but in presence of hyaluronidase 
(Hyal) the dye molecules are released from the SWNT and fluorescence is recovered. 
(modified from ref.86)  
e) Ultrasound (top) and PAI (bottom) of the bottom hind limb SCC7 tumor of mice pre-
injection and at 2 h and 20 h post-injection of Cy5.5-HAC-SWNT.86 
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Figure 9. Optical properties of conjugated polymers and application to imaging the 
extravascular target folate receptor in breast cancer. 
a) Absorption spectra of targeted conjugated polymer (green line) (shown in b and c) 108, 
porphyrin based NPs encapsulating perfluorocarbon gas (red line)113, ICG (light blue, 
dashed line) and FA-ICG-PLGA-lipid polymer nanoparticle (PNP) (dark blue line)122. 
Conjugated polymers often possess a broadband absorption profile whereas the porphyrin 
based NPs show a narrow absorption peak in the NIR allowing a clearer identification in PAI. 
The absorption of PNPs with integrated signaling compounds show in general the 
characteristics of the chosen signaling compound (c.f. ICG and FA-ICG-PLGA-lipid PNP in 
a). 
b) Schematic illustration of the structure of folate-CP dots including the conjugated polymer 
PFTTQ, DSPE-PEG2000, and DSPE-PEG2000-folate.108 
c) PAI of mice bearing FR+ve MCF-7 breast cancer xenografts (A) before systemic 
administration of the probe, (B + C) 3 hours after administration of folate-CP dots and 3 
hours after administration of untargeted CP-dots (D +E).108 
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